Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Lapatinib|DRUG: Lapatinib-Placebo
Sponsor: Institute of Cancer Research, United Kingdom
Collaborators: GlaxoSmithKline